about
Cytotoxic and immune-sensitizing properties of nitric oxide-modified Saquinavir in iNOS-positive human melanoma cells.The antitumor properties of a nontoxic, nitric oxide-modified version of saquinavir are independent of Akt.Activity, but not mRNA expression of gelatinases correlates with susceptibility to experimental autoimmune encephalomyelitis.Inducible nitric oxide synthase activation by interleukin-17.Cell death of spinal cord ED1(+) cells in a rat model of multiple sclerosis.Correlation of Gut Microbiota Composition with Resistance to Experimental Autoimmune Encephalomyelitis in Rats.Astrocytes in the tempest of multiple sclerosis.CXCL12 in control of neuroinflammation.CXCL12: role in neuroinflammation.Tenascins and inflammation in disorders of the nervous system.The NO-modified HIV protease inhibitor as a valuable drug for hematological malignancies: Role of p70S6K.Short term exposure to ethyl pyruvate has long term anti-inflammatory effects on microglial cells.Cell-based Tolerogenic Therapy, Experience from Animal Models of Multiple Sclerosis, Type 1 Diabetes and Rheumatoid Arthritis.Betulinic acid regulates generation of neuroinflammatory mediators responsible for tissue destruction in multiple sclerosis in vitro.Anticancer potential of (pentamethylcyclopentadienyl)chloridoiridium(III) complexes bearing κP and κP,κS-coordinated Ph2 PCH2 CH2 CH2 S(O)x Ph (x=0-2) ligands.Biological activity of neutral and cationic iridium(III) complexes with κP and κP,κS coordinated Ph₂PCH₂S(O)xPh (x = 0-2) ligands.Melanoma tumor inhibition by tetrachlorido(O,O'-dibutyl-ethylenediamine-N,N'-di-3-propionate)platinum(IV) complex: in vitro and in vivo investigations.Novel methylene modified cyclohexyl ethylenediamine-N,N'-diacetate ligands and their platinum(IV) complexes. Influence on biological activity.Regional cytokine responses to pulmonary aspergillosis in immunocompetent rats.In vitro and in vivo anticancer action of Saquinavir-NO, a novel nitric oxide-derivative of the protease inhibitor saquinavir, on hormone resistant prostate cancer cells.Induction of caspase-independent apoptotic-like cell death of mouse mammary tumor TA3Ha cells in vitro and reduction of their lethality in vivo by the novel chemotherapeutic agent GIT-27NO.Novel nitric oxide-donating compound (S,R)-3-phenyl-4,5-dihydro-5-isoxazole acetic acid-nitric oxide (GIT-27NO) induces p53 mediated apoptosis in human A375 melanoma cells.Anticancer properties of the novel nitric oxide-donating compound (S,R)-3-phenyl-4,5-dihydro-5-isoxazole acetic acid-nitric oxide in vitro and in vivo.A potent immunomodulatory compound, (S,R)-3-Phenyl-4,5-dihydro-5-isoxazole acetic acid, prevents spontaneous and accelerated forms of autoimmune diabetes in NOD mice and inhibits the immunoinflammatory diabetes induced by multiple low doses of strepAcidosis affects tumor cell survival through modulation of nitric oxide release.Interleukin-17 stimulates inducible nitric oxide synthase-dependent toxicity in mouse beta cells.[Pt(HPxSC)Cl(3)], a novel platinum(IV) compound with anticancer properties.Aloe emodin decreases the ERK-dependent anticancer activity of cisplatin.Iron protects astrocytes from 6-hydroxydopamine toxicity.Novel ruthenium complex K2[Ru(dmgly)Cl4].2H2O is toxic to C6 astrocytoma cell line, but not to primary rat astrocytes.Iron down-regulates macrophage anti-tumour activity by blocking nitric oxide production.Immunosuppressants leflunomide and mycophenolic acid inhibit fibroblast IL-6 production by distinct mechanisms.Necrotic tumor cells oppositely affect nitric oxide production in tumor cell lines and macrophages.Amphotericin B potentiates the activation of inducible nitric oxide synthase and causes nitric oxide-dependent mitochondrial dysfunction in cytokine-treated rodent astrocytes.Down-regulation of multiple low dose streptozotocin-induced diabetes by mycophenolate mofetil.The role of interleukin-17 in inducible nitric oxide synthase-mediated nitric oxide production in endothelial cells.Immunosuppressive and anti-inflammatory action of antioxidants in rat autoimmune diabetes.Saquinavir-NO inhibits S6 kinase activity, impairs secretion of the encephalytogenic cytokines interleukin-17 and interferon-gamma and ameliorates experimental autoimmune encephalomyelitis.Cucurbitacin E Potently Modulates the Activity of Encephalitogenic Cells.A comparative analysis of multiple sclerosis-relevant anti-inflammatory properties of ethyl pyruvate and dimethyl fumarate.
P50
Q34179539-6429A5FD-945B-4DB3-B217-74C9188E27AAQ34979356-35AA6780-DBD7-4497-AA68-75CD9B8B264EQ35564778-979B4884-10A3-4D14-89AD-502644D0BF1DQ35640431-835BAB2A-CBEE-408C-92CA-5B8259600F88Q36089786-B27F4F04-A5CC-4A57-9E19-2BC0E9CA823EQ37503790-CC2293F8-FDDA-47BC-A1C7-7F9D070B11B8Q37858667-95ABFCB7-7898-4988-B53E-B2D4B9C29F4DQ37990784-7FEAC1D2-F849-4ECA-BA1F-6991BB49FD2CQ38000920-47DD85E7-7904-41CB-B165-48B608825200Q38069948-BAAEDB62-76A9-4C92-A383-6C1B38DA0643Q38848393-920F4154-E0BD-4603-A9AA-791DFC8EDA1EQ38866243-000DDD0F-5EDE-4308-BEA7-281856835813Q38959834-CDACF4BA-9A5C-4E6E-8ACC-7171B9A2F455Q39014507-0F19F499-B16E-4656-86E3-C48E870D7F74Q39029785-9B6B4FFD-9D44-4306-AEE3-965DFF9DF9F0Q39094988-7A3080DE-FF61-431A-B1ED-71493FF0EF4DQ39270889-BCBB1074-3DCA-478E-9C14-98DF8212B0BFQ39389516-C490F627-6596-45F0-90B4-6AC891D8999CQ39394360-DD372FFB-B7D9-4659-85CD-8DDF482DEB36Q39602151-6693E998-B27D-4E0C-9462-ACEEA8433085Q39746181-FB1A6E1A-06F4-4AE2-ABBA-71C13423918EQ39984965-05411A13-A840-4B90-8F22-33957ADA2F14Q40001479-C02A8D89-696C-4868-8054-C586B913A43BQ40200249-DF8CDDCC-9610-4FBC-86A4-5363926385BCQ40329658-E7C31A0A-FA7E-46A6-9363-1BDADF632F14Q40356004-D6B7A647-32ED-483F-87E1-4D34F3C357DDQ40406554-14388D9B-4CAC-407F-84E1-6F21EC51522FQ40419631-BC90F57D-8D1D-46E1-99A6-79A2B37C88D5Q40438209-1CF798FC-365B-4F71-B836-FC71B0922B7FQ40492750-9C68C7F2-530A-4849-9E40-C4FDFFC060BEQ40545617-9ACD5E59-1D70-4C8A-ACAA-875AC7A7786AQ40701768-CD6B11B9-0AC7-4D64-8707-1854B4671775Q40715232-96DCBAE8-0F61-4945-9544-B97CC4624FFAQ40787438-89B9FD18-02ED-4FA8-B626-EF2B4EBDB49BQ44091857-46B9AE5E-93F6-4BD3-A95F-77F13B9911E9Q44434104-1C2F4E0F-2216-4B4D-85D8-8E34E276DBADQ44878800-D5673423-089C-4324-801A-D7E9F4E3A4E9Q45098771-3BBC4E4C-CCFD-4779-9C5C-B9FC81C81C18Q46542430-C9CDEFE7-2951-4400-ADCA-61D4AFA6F142Q46772862-C41D4FC1-8382-46E9-BC20-55E83723B44E
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Đorđe Miljković
@ast
Đorđe Miljković
@en
Đorđe Miljković
@es
Đorđe Miljković
@nl
Đorđe Miljković
@sl
type
label
Đorđe Miljković
@ast
Đorđe Miljković
@en
Đorđe Miljković
@es
Đorđe Miljković
@nl
Đorđe Miljković
@sl
prefLabel
Đorđe Miljković
@ast
Đorđe Miljković
@en
Đorđe Miljković
@es
Đorđe Miljković
@nl
Đorđe Miljković
@sl
P106
P31
P496
0000-0002-5613-9306